Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

The user believes Retrograde Alopecia may be linked to vitamin imbalances, specifically from taking too much Vitamin E, A, Zinc, and Selenium, and suggests it could be a middle ground between Androgenic Alopecia and Telogen Effluvium. Treatments for hair loss mentioned include Androgen inhibitors and improving lifestyle factors like nutrition and sleep, with topical melatonin also recommended for Retrograde Alopecia.

8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.

The user experienced significant hair regrowth using 1mg finasteride every other day, 5% minoxidil twice daily, and ketoconazole shampoo. The progress was noted as impressive, with some users questioning the authenticity of the results.

User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

A 20-year-old female is experiencing hairline loss and seeks effective natural remedies or affordable drugstore treatments. She has tried flax seeds and aloe vera without success.

A 20-year-old is experiencing severe diffuse thinning and shedding despite using oral minoxidil for 12 months and dutasteride for 8 months, after previously trying finasteride. They are frustrated with the lack of improvement and considering trying RU58841.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

A 22-year-old male has been experiencing widespread hair loss for over four years, including pain and significant shedding. Treatments tried include ketoconazole shampoo, fluocinonide topical solution, biotin, ACV, and dry shampoo, but none have been effective.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

A 23-year-old male switched to a topical solution containing Fin 0.1% and Min 5% from a previous solution with Fin 1% and Min 5%, noticing increased hair shedding. He is concerned about losing around 50 hairs while using ketoconazole shampoo.

The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.

Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.

The user reintroduced RU58841 and noticed increased shedding and visible thinning. They have also been using dutasteride and oral minoxidil for 2 years.

Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hair follicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.

The user is experiencing hair loss despite using dutasteride, minoxidil, and ketoconazole shampoo, and is concerned about continued shedding. Suggestions include checking for nutrient deficiencies, consulting a dermatologist, and considering other potential causes like seborrheic dermatitis or telogen effluvium.

The conversation discusses hair thinning and treatments like finasteride, dutasteride, oral and topical minoxidil, and RU58841. Users share experiences with retrograde alopecia, hair transplants, and stress-related hair loss, while also considering thyroid issues and other potential causes.

The user is experiencing hair shedding despite starting finasteride 4 months ago, with no signs of miniaturization. They are seeking advice after normal blood tests and similar family experiences.

The user has been using minoxidil, microneedling, and finasteride for hair loss without improvement and is considering tretinoin, but concerns about shedding persist. Another user suggests trying dutasteride instead of finasteride, as both tretinoin and microneedling can irritate the skin.

The user is exploring alternatives to hair transplants due to a weak donor area and is currently using finasteride, minoxidil, dermapen, low-level laser therapy, Nizoral shampoo, and a high-protein diet. They plan to switch to dutasteride and consider adding RU58841, while rejecting hair systems and considering a buzz cut.

A user has been losing hair for two and a half years after a tropical trip and illness. A dermatologist prescribed betamethasone valerate 0.1% lotion, but the user is unsure if it's safe or effective for general hair loss.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.

The user experienced significant hair improvement with minoxidil and finasteride but later faced shedding and diffused thinning after developing seborrheic dermatitis. They are seeking advice after trying treatments like ketoconazole, coal tar shampoos, fluconazole, and hydrocortisone cream.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.